Pharmacist Information Hub

Understanding the current vaping laws

Pharmacists have dispensed vaping products since late 2021. The new regulatory changes reaffirm pharmacists at the heart of smoking cessation and envisage that they will:

  1. Provide initial information about therapeutic vaping and when it may be appropriate for a patient.
  2. Act as a conduit for patients, depending on their needs, to:
    • Organisations that can provide behavioural support alone; or
    • Prescribers that can provide behavioural support and prescription medicines, including higher-concentration vapes.
  3. Ensure supply of S3 or S4 vapes as part of a cessation strategy.

S3

Total nicotine concentration of 20 mg/mL or less

Eligible for supply as an S3 product*

S4

Total nicotine concentration of 50 mg/mL or less

Dispensed only under prescription
*subject to the requirements of the Therapeutic Goods (Medicines and OTG—Authorised Supply) Rules 2022.

What are the changes to the vaping laws?

Increases standards for prescribed vaping products

Establishes a list of TGA-notified products

Creates a class of pharmacist-only S3 (low concentration) vapes

Provides continued therapeutic access to S4 (higher-concentration) vapes under prescription

Ensures patients are directed to cessation support services

Back to basics: therapeutic vaping in person-centred care

Few patients will have considered vaping as a smoking cessation tool.

In alignment with the person-centred care1 approach, the new rules will see patients approaching pharmacists for evidence-based advice about therapeutic vaping and whether it may be appropriate for them.

Pharmacists are ideally positioned to assist those in your community who urgently need new strategies to tackle tobacco dependence – one of the foremost challenges in primary healthcare.

How person-centred care applies to therapeutic vaping
Work in partnership with your patient Support patients to make informed healthcare decisions about the suitability of vaping for them
Provide advice to them Provide patients with current evidence-based advice on therapeutic vaping's role in the cessation toolkit
Work in collaboration with a prescriber Work in collaboration with prescribers to optimise the delivery of smoking cessation strategies to your patient
Supplying and Dispensing Therapeutic Vapes
Nicovape Q products are TGA notified therapeutic vaping goods indicated for smoking cessation or the management of nicotine dependence. TGA Notification ID numbers: VG-2024-NTF-00234, VG-2024-NTF-00241, VG-2024-NTF-00240, VG-2024-NTF-00235, VG-2024-NTF-00242, VG-2024-NTF-00239, VG-2024-NTF-00237, VG-2024-NTF-00243, VG-2024-NTF-00238, VG-2024-NTF-00236.

© 2024 Liber Pharmaceuticals Ltd. All content

iNRT Healthcare is operated by Liber Pharmaceuticals for the purpose of furthering healthcare education regarding Nicotine Vaping Products (NVPs) within the Australian medical framework. Liber has no affiliation with the tobacco industry, their affiliates, or any organisations or individuals engaged in lobbying on their behalf.

This site is intended for use only by Australian-registered healthcare professionals with an interest in smoking cessation. It is not intended for use by consumers.